TIDAL-01

N/A

Report date: 2026/04/17 10:36:26

Base Information

Drug NameTIDAL-01

Drug Alias NameAdoptive Cell Therapy with Tumor-infiltrating Lymphocytes（H Lee Moffitt Cancer Center & Research Institute）Adoptive Cell Therapy with TIL（H Lee Moffitt Cancer Center & Research Institute）TIDAL-01TBio-4101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsUveal melanomaSkin MelanomaCarcinoma, Non-Small-Cell Lung +[9]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMyst Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTurnstone Biologics Corp H Lee Moffitt Cancer Center & Research Institute

Active IndicationsN/A

Inactive IndicationsUveal melanomaSkin MelanomaCarcinoma, Non-Small-Cell Lung +[9]

Other Information

ATC CodeN/A